Kaviaar schreef op 10 april 2024 12:51:
Stifel Initiates Research Coverage of ONWARD® Medical with
a Buy Rating and Target Price of EUR 12.00EINDHOVEN, the Netherlands — April 9, 2024 — ONWARD Medical N.V. (Euronext: ONWD),
the medical technology company creating innovative therapies to restore movement, function,
and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-
based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy
rating and Target Price of EUR 12.00 per share. This is a premium of 140% to the closing price
of EUR 5.00 on April 8, 2024.
The initiation report was published April 8, 2024. Stifel joins four other banks whose analysts
cover ONWARD Medical, all of which maintain Buy ratings and Target Prices at substantial
premiums to the current share price.
“Stifel’s initiation of coverage reflects the value they place on the strategic positioning of our
brain-computer interface (BCI) platform as well as their strong confidence in our ability to
achieve this year’s milestones, which include the planned commercialization of our ARC-EX®
platform later this year,” said Dave Marver, CEO of ONWARD Medical. “Stifel is the largest
provider of global small-cap equity research, and we are gratified they recognize the value
ONWARD can create for investors in coming quarters.”
To learn more about ONWARD Medical’s commitment to partnering with the SCI community to
develop innovative solutions for restoring movement, function, and independence after spinal
cord injury, please visit ONWD.com.
*All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-
BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are
investigational and not available for commercial use.